Benefits
Lower body strength improvement
At 12 weeks, the Strengthera cohort showed a 4.2x improvement in lower body strength (1RM leg extension) vs. placebo plus exercise program — a clinically meaningful gain in a population where age-related muscle loss is a primary health concern.
Grip strength and muscle endurance
Subjects taking Strengthera showed a 4.5x improvement in grip strength and a 1.5x improvement in muscle endurance (repetitions to failure at 80% 1RM) vs. placebo at 12 weeks — improvements that translate directly to functional independence and fall prevention.
Walking capacity and functional mobility
An astonishing 90% improvement in walking capacity (6-minute walk test) was observed in the Strengthera group vs. placebo — one of the most meaningful functional outcomes for aging adults and a direct measure of cardiovascular and musculoskeletal health.
mTOR activation and muscle protein synthesis
The proposed mechanism of action includes mTOR pathway activation, inhibition of muscle protein catabolism, mitochondrial efficiency enhancement, and endothelial nitric oxide synthase (eNOS) stimulation — a multi-pathway approach to preserving and building muscle in aging tissue.
Mechanism of action
Mitochondrial efficiency enhancement
Strengthera's primary proposed mechanism is enhancement of mitochondrial energy metabolism efficiency in muscle tissue, making the same amount of exercise more productive and allowing muscle cells to generate more force per ATP consumed.
mTOR pathway activation
The botanical combination activates mTOR (mechanistic target of rapamycin), the master regulator of muscle protein synthesis. mTOR activation is required for muscle hypertrophy and is the same pathway stimulated by resistance exercise and leucine.
Catabolic inhibition and eNOS stimulation
Strengthera inhibits muscle protein catabolism pathways (reducing proteolysis), while simultaneously stimulating endothelial nitric oxide synthase — improving blood flow and nutrient delivery to working muscle tissue.
Clinical trials
12-week randomized, double-blind, placebo-controlled study in 92 healthy men and women aged 55–70. Participants received 650 mg/day Strengthera or placebo alongside a standardized at-home exercise program. Assessments at baseline, 4, 8, and 12 weeks.
99 young men (age 22 ± 3) randomized to one of four arms: A1 (425 mg SMI + 1 RET set), A2 (850 mg SMI + 1 RET set), P1 (placebo + 1 RET set), P2 (placebo + 2 RET sets). 3×/week resistance training (bench press + leg extension) at 80% 1-RM for 8 weeks. Same Sphaeranthus indicus + Mangifera indica blend (LI12542F6) as RipFACTOR® and TestFACTOR®.
Resistance training significantly increased 1-RM, repetitions to failure, and testosterone in all groups (p<0.05), but the supplemented groups showed greater gains than placebo or doubled-volume placebo. Validates SMI as an ergogenic adjunct to RET. Foundational young-male trial; (n=40 young men) provides additional support for muscle strength and endurance. A 92-pt 55-70 trial is pending publication for the over-55 demographic.
Clinical trial of SMI botanical blend (425 mg and 850 mg/day) vs. placebo in 99 men aged 22±3 performing resistance training for 8 weeks.
99 healthy young men. 8-week resistance training + supplementation protocol.
Both SMI doses significantly augmented bench press and leg extension strength and repetitions-to-failure beyond exercise alone. Testosterone levels increased significantly in supplemented groups. Published in Frontiers in Nutrition, 2024.